Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).
Harada T, Sasaki T, Ishii H, Takemoto S, Hisamatsu Y, Saito H, Yoneshima Y, Komiya K, Kashiwabara K, Naoki K, Ogawa T, Takeoka H, Saruwatari K, Ito K, Tsuchiya-Kawano Y, Mizuno K, Shimose T, Shioyama Y, Okamoto I. Harada T, et al. Among authors: kashiwabara k. Thorac Cancer. 2024 Oct;15(29):2128-2135. doi: 10.1111/1759-7714.15444. Epub 2024 Sep 8. Thorac Cancer. 2024. PMID: 39245951 Free PMC article. Clinical Trial.
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T. Saruwatari K, et al. Among authors: kashiwabara k. Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195. Anticancer Res. 2019. PMID: 30711977
Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S, Ichiyasu H, Ikeda T, Inaba M, Kashiwabara K, Sadamatsu T, Sato N, Akaike K, Okabayashi H, Saruwatari K, Tomita Y, Saeki S, Hirata N, Yoshinaga T, Fujii K. Hamada S, et al. Among authors: kashiwabara k. BMC Pulm Med. 2019 Apr 2;19(1):72. doi: 10.1186/s12890-019-0838-2. BMC Pulm Med. 2019. PMID: 30940113 Free PMC article.
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai T, Saruwatari K, Ikeda T, Moriyama E, Kashiwabara K, Shingu N, Iyonaga K, Inaba M, Ajishi Y, Honda C, Hirosako S, Maruyama H, Kakiuchi Y, Eida H, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Jodai T, et al. Among authors: kashiwabara k. Int J Clin Oncol. 2021 Jan;26(1):78-86. doi: 10.1007/s10147-020-01789-5. Epub 2020 Sep 23. Int J Clin Oncol. 2021. PMID: 32965577
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N, Nakashima C, Yoshida H, Matsumoto N, Iwanaga K, Ebi N, Nishiyama A, Yatera K, Kuyama S, Fukuda M, Ushijima S, Umeguchi H, Harada D, Kashiwabara K, Suetsugu T, Fujimoto N, Tanaka F, Uramoto H, Yoshii C, Nakatomi K, Koh G, Seki N, Aoe K, Nosaki K, Inoue K, Takamori A, Kawaguchi A. Sueoka-Aragane N, et al. Among authors: kashiwabara k. Cancer Med. 2021 Jun;10(12):3873-3885. doi: 10.1002/cam4.3929. Epub 2021 May 12. Cancer Med. 2021. PMID: 33982444 Free PMC article.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Tanaka H, Inaba M, Haruyama T, Nakamura J, Kishikawa T, Nakashima M, Iwasa K, Fujiwara K, Kohyama T, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Ishida H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Yokoyama T, Gemba K, Tsuda T, Nakagawa H, Ono H, Shimizu T, Nakamura M, Kusumoto S, Hayashi R, Shirasaki H, Ochi N, Aoe K, Kanaji N, Kashiwabara K, Inoue H, Seki N. Tanzawa S, et al. Among authors: kashiwabara k. Ther Adv Med Oncol. 2021 Feb 27;13:1758835921998588. doi: 10.1177/1758835921998588. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33717228 Free PMC article.
Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
Kashiwabara K, Fujii S, Tsumura S, Sakamoto K. Kashiwabara K, et al. J Cancer Res Clin Oncol. 2021 Jan;147(1):287-293. doi: 10.1007/s00432-020-03344-1. Epub 2020 Aug 6. J Cancer Res Clin Oncol. 2021. PMID: 32761377 Clinical Trial.
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Osoegawa A, Yamaguchi M, Nakamura T, Morinaga R, Tanaka K, Kashiwabara K, Miura T, Suetsugu T, Harada T, Asoh T, Taguchi K, Nabeshima K, Kishimoto J, Sakai K, Nishio K, Sugio K. Osoegawa A, et al. Among authors: kashiwabara k. JTO Clin Res Rep. 2021 May 14;2(7):100191. doi: 10.1016/j.jtocrr.2021.100191. eCollection 2021 Jul. JTO Clin Res Rep. 2021. PMID: 34590037 Free PMC article.
228 results